Skip to main content
Oncology Hematologic Cancer

Hematologic Cancer

An extremely rare subtype of lymphoma

Primary pulmonary DLBCL is a rare clinical condition with nonspecific clinical manifestations, posing significant challenges for diagnosis. This patient was initially misdiagnosed as having organizing pneumonia.

Read more

Editor's Choice

Evolving strategies for addressing CAR T-cell toxicities

An overview of the most common toxicities associated with CAR T-cell therapy, highlighting risk factors, implications for critical care, and ongoing work to optimize patient experience and mitigate toxicities.

Transplantation can be omitted for certain MCL patients

Use of autologous transplantation does not improve the survival of people with mantle cell lymphoma and undetectable minimal residual disease after induction therapy.

Featuring the official presentation video

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Novel CAR T-cell therapy shows potential for B-cell ALL

Obecabtagene autoleucel has demonstrated promising antitumor activity and safety in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now

Case Studies

An extremely rare subtype of lymphoma

Primary pulmonary DLBCL is a rare clinical condition with nonspecific clinical manifestations, posing significant challenges for diagnosis. This patient was initially misdiagnosed as having organizing pneumonia.

A fatal side effect of a novel drug

Following treatment with the bispecific T-cell engager epcoritamab, a patient with relapsed DLBCL developed pleural effusion, which proved fatal despite aggressive management. Regular monitoring is crucial to identify and manage severe inflammatory reactions.

ALS in a patient with CLL and drug-related SLR

A man with a skin rash and left leg weakness was diagnosed with sarcoid-like reaction due to treatment for chronic lymphocytic leukemia, and ultimately also amyotrophic lateral sclerosis when the motor symptoms progressed.

Episode 9: The gut microbiome and CAR T-cell therapy

How do nutrition, supplements and antibiotics impact patient outcomes?

Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe
Listen now

Current Reviews

Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis

Blood cancers or hematological malignancies originate from the blood-forming tissue, i.e., bone marrow or from the immune system, and can be classified as leukemias, myelomas, and lymphomas [ 1 ]. Over the past few decades, hematological …

Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma

The management of marginal zone lymphoma (MZL), an indolent B-cell non-Hodgkin lymphoma, requires a personalized and adaptive approach due to its clinical and prognostic heterogeneity. We believe treatment should emphasize a balanced strategy …

Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements

According to the guidelines, the primary treatment for multiple myeloma is still based on drugs such as carfilzomib, lenalidomide, or daratumumab. However, patients with relapsed/refractory multiple myeloma (RRMM) may be insensitive or develop …

NPM1 Measurable Residual Disease: A Narrative Review

Acute myeloid leukemia (AML) with mutated NPM1 (Nucleophosmin 1) is a distinct entity in the 5th edition of the World Health Organization (WHO) Classification as well as a favourable risk category in the 2022 European LeukemiaNet (ELN) …

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

  • Webinar | 19-02-2024 | 17:30 (CET)

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Watch now

CME & eLearning

SPONSORED

Webinar

1.5 European CME credits (ECMEC®s)

A series of patient cases underpin this interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.

Sponsored by:
  • Kyowa Kirin
Developed by: Springer Healthcare

Symposium (Link opens in a new window)

An independent symposium at the 10th COMy World Congress focusing on BCMA-targeting strategies for the treatment of multiple myeloma. Gain insights into the latest clinical data and the implications for clinical practice.

Supported by:
  • GlaxoSmithKline
Developed by: Springer Healthcare IME
SPONSORED

Webinar

In this live webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK. 

Sponsored by:
  • Novartis Pharma AG
Developed by: Springer Healthcare

Further Reading

Discovery of a second, distinct development pattern of leukemic conversion from paroxysmal nocturnal hemoglobinuria

The incidence of leukemic conversion during the clinical course of paroxysmal nocturnal hemoglobinuria (PNH) has been reported to be 0.6–2.9%. Such an association is logically linked to the progression of PNH to acute leukemia, especially the M6 …

Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia

T-cell large granular lymphocytic leukemia (T-LGLL) is a rare hematologic neoplasm characterized by clonal expansion of CD3 + cytotoxic T lymphocytes and a highly heterogeneous clinical course. Conventional therapy primarily includes …

Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia

The colony-stimulating factor 3 receptor (CSF3R) plays an essential role in differentiation, growth, and survival of granulocytes. Driver mutations in CSF3R gene represent a diagnostic marker of chronic neutrophilic leukemia (CNL). Less commonly …

The molecular impact of miR-326 in acute lymphoblastic leukemia and its cross talk with P53

MiR-326 downregulation is strongly associated with multidrug resistance (MDR) and has been identified as an adverse prognostic biomarker for pediatric acute lymphoblastic leukemia (pALL). The choice to study miR-326 as a tumor suppressor in cancer …

Related topics

ALS in a patient with CLL and drug-related SLR

A man with a skin rash and left leg weakness was diagnosed with sarcoid-like reaction due to treatment for chronic lymphocytic leukemia, and ultimately also amyotrophic lateral sclerosis when the motor symptoms progressed.

Read more

An extremely rare subtype of lymphoma

Primary pulmonary DLBCL is a rare clinical condition with nonspecific clinical manifestations, posing significant challenges for diagnosis. This patient was initially misdiagnosed as having organizing pneumonia.

Read more